Christopher Trevisani

3PUBLICATIONS
57CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (3)

|Nov 15, 2024
Author Correction: Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial.

Steven M Horwitz, Ajit J Nirmal, Jahan Rahman

|Jun 17, 2024
Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial.

Steven M Horwitz, Ajit J Nirmal, Jahan Rahman

|Jan 22, 2024
KLRG1 Cell Depletion as a Novel Therapeutic Strategy in Patients with Mature T-Cell Lymphoma Subtypes.

Bimarzhan Assatova, Robert Willim, Christopher Trevisani

Pageof 1